Imperial College London
Portrait Picture

DrLouisePaterson

Faculty of Medicine, Department of Brain Sciences

Advanced Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 7028l.paterson

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Paterson:2015:10.1177/0269881115596155,
author = {Paterson, LM and Flechais, RSA and Murphy, A and Reed, LJ and Abbott, S and Boyapati, V and Elliott, R and Erritzoe, D and Ersche, KD and Faluyi, Y and Faravelli, L and Fernandez-Egea, E and Kalk, NJ and Kuchibatla, SS and McGonigle, J and Metastasio, A and Mick, I and Nestor, L and Orban, C and Passetti, F and Rabiner, EA and Smith, DG and Suckling, J and Tait, R and Taylor, EM and Waldman, AD and Robbins, TW and Deakin, JFW and Nutt, DJ and Lingford-Hughes, AR},
doi = {10.1177/0269881115596155},
journal = {Journal of Psychopharmacology},
pages = {943--960},
title = {The Imperial College Cambridge Manchester (ICCAM) platform study: an experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: study description},
url = {http://dx.doi.org/10.1177/0269881115596155},
volume = {29},
year = {2015}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Drug and alcohol dependence are global problems with substantial societal costs. There are few treatments for relapse prevention and therefore a pressing need for further study of brain mechanisms underpinning relapse circuitry. The Imperial College Cambridge Manchester (ICCAM) platform study is an experimental medicine approach to this problem: using functional magnetic resonance imaging (fMRI) techniques and selective pharmacological tools, it aims to explore the neuropharmacology of putative relapse pathways in cocaine, alcohol, opiate dependent, and healthy individuals to inform future drug development. Addiction studies typically involve small samples because of recruitment difficulties and attrition. We established the platform in three centres to assess the feasibility of a multisite approach to address these issues. Pharmacological modulation of reward, impulsivity and emotional reactivity were investigated in a monetary incentive delay task, an inhibitory control task, and an evocative images task, using selective antagonists for µ-opioid, dopamine D3 receptor (DRD3) and neurokinin 1 (NK1) receptors (naltrexone, GSK598809, vofopitant/aprepitant), in a placebo-controlled, randomised, crossover design. In two years, 609 scans were performed, with 155 individuals scanned at baseline. Attrition was low and the majority of individuals were sufficiently motivated to complete all five sessions (n=87). We describe herein the study design, main aims, recruitment numbers, sample characteristics, and explain the test hypotheses and anticipated study outputs.
AU  - Paterson,LM
AU  - Flechais,RSA
AU  - Murphy,A
AU  - Reed,LJ
AU  - Abbott,S
AU  - Boyapati,V
AU  - Elliott,R
AU  - Erritzoe,D
AU  - Ersche,KD
AU  - Faluyi,Y
AU  - Faravelli,L
AU  - Fernandez-Egea,E
AU  - Kalk,NJ
AU  - Kuchibatla,SS
AU  - McGonigle,J
AU  - Metastasio,A
AU  - Mick,I
AU  - Nestor,L
AU  - Orban,C
AU  - Passetti,F
AU  - Rabiner,EA
AU  - Smith,DG
AU  - Suckling,J
AU  - Tait,R
AU  - Taylor,EM
AU  - Waldman,AD
AU  - Robbins,TW
AU  - Deakin,JFW
AU  - Nutt,DJ
AU  - Lingford-Hughes,AR
DO  - 10.1177/0269881115596155
EP  - 960
PY  - 2015///
SN  - 1461-7285
SP  - 943
TI  - The Imperial College Cambridge Manchester (ICCAM) platform study: an experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: study description
T2  - Journal of Psychopharmacology
UR  - http://dx.doi.org/10.1177/0269881115596155
UR  - http://hdl.handle.net/10044/1/32288
VL  - 29
ER  -
Download